Information Provided By:
Fly News Breaks for February 26, 2018
SAGE
Feb 26, 2018 | 07:38 EDT
Morgan Stanley analyst Matthew Harrison started Sage Therapeutics with an Overweight rating and $225 price target, stating that he sees brexanolone for post-partum depression providing a "solid base" that can generate $775M in peak U.S. sales. The real long-term value he sees, though, is from next-gen agent SAGE-217, which Harrison said has initial "robust" data in depression and expansion opportunities into bipolar disorder and insomnia.
News For SAGE From the Last 2 Days
SAGE
SAGE
SAGE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.